Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alpha Tau Medical Ltd.DRTS · Entity 4784 | Director | March 18, 2026 | March 18, 2026 |
| Lifeward Ltd.LFWD · Entity 7620 | Director | March 25, 2026 | March 27, 2026 |
| Nano Dimension Ltd.NNDM · Entity 5842 | Director | August 21, 2026 | August 25, 2026 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director · President and CEO | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alpha Tau Medical Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,986 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,986 |
| Restricted Share UnitsSEC Table I · non-derivative | Direct | 7,767 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,767 F1: These ordinary shares represent the unvested portion of a grant of restricted share units, which vests in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service. |
| Restricted Share UnitsSEC Table I · non-derivative | Direct | 4,680 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,680 F2: These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2035-05-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: These are options to acquire ordinary shares, which options will vest in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.41 · Expires 2036-03-09 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares represent the unvested portion of a grant of restricted share units, which vests in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service.
F2: These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
F3: These are options to acquire ordinary shares, which options will vest in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service.
F4: These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
Lifeward Ltd.
Report date March 25, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, no par value per shareSEC Table I · non-derivative | Direct | 7,657 |
Reported balance
After 2026-03-25 transaction · row 1
1 source rowRow 1 · 2026-03-25 · Grant · Acquired 7,657 · Balance 7,657 F1: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date.
Nano Dimension Ltd.
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-08-21 transaction · row 1
1 source rowRow 1 · 2026-08-21 · Other · Disposed 10,000 · Balance 30,000 F1: The call option contracts (the "Options") was written before the Reporting Person became a Section 16 insider of the Issuer and therefore was reported on the Reporting Person's Form 3 filed with the Securities and Exchange Commission on August 25, 2026. The shares were sold in connection with the exercise of the Option by a third party. |
| Call options (obligation to sell)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2026-08-21 | Direct | 0 |
Reported balance
After 2026-08-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-21 · Other · Disposed 100 · Balance 0 F2: The Options were exercised in accordance with their terms, and no investment decision was made by the Reporting Person in connection therewith. The Options were exercisable at any time prior to the Expiration Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The call option contracts (the "Options") was written before the Reporting Person became a Section 16 insider of the Issuer and therefore was reported on the Reporting Person's Form 3 filed with the Securities and Exchange Commission on August 25, 2026. The shares were sold in connection with the exercise of the Option by a third party.
F2: The Options were exercised in accordance with their terms, and no investment decision was made by the Reporting Person in connection therewith. The Options were exercisable at any time prior to the Expiration Date.
ORAMED PHARMACEUTICALS INC.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,140,505 |
Ending reported balance
After 2026-09-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-24 · Grant · Acquired 349,497 · Balance 3,771,740 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. Row 2 · 2026-09-24 · Grant · Acquired 368,765 · Balance 4,140,505 F2: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2029-09-11 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-24 · Disposition to issuer · Disposed 196,500 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F3: The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2030-01-08 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-24 · Disposition to issuer · Disposed 190,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F4: The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2027-06-30 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-24 · Disposition to issuer · Disposed 49,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F5: The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-24 · Disposition to issuer · Disposed 97,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F6: The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-24 · Disposition to issuer · Disposed 150,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F7: The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-03 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-24 · Disposition to issuer · Disposed 107,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F8: The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy wholly-owned corporation | 126,000 |
Reported balance
Holding disclosure · report date 2026-09-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 126,000 |
Filing footnotes · ownership attribution and instrument terms
F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.
F2: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 368,765 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.
F3: The canceled option provided for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.
F4: The canceled option provided for vesting in 4 equal installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.
F5: The canceled option provided for vesting in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the issuer's share price reaching $8.00, $9.50 and $12.50 per share, respectively. Only the first share price target was achieved, and accordingly only 49,000 of the options vested.
F6: The canceled option provided for vesting in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.
F7: The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.
F8: The canceled option provided for vesting in 4 equal installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2019 Filed Sep 16, 2019 22:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 196,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-018199 · ownership.xml · derivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,500 Underlying: Common Stock · 196,500 shares Expires 2029-09-12 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. F1 · derivative.exercise_date: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:55 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 196,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-003334 · ownership.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,500 Underlying: Common Stock · 196,500 shares Expires 2029-02-26 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Sep 16, 2019 22:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock Option (right to buy) · Derivative | 196,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-018199 · ownership.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 196,500 shares Expires 2029-02-26 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. F1 · derivative.exercise_date: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 21:11 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 122 | $5.92 | $722.18 |
DisclosureSEC source: 0001213900-18-009128 · ownership.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,209 F1 · price: On July 12, 2018, Mr. Kidron paid to Oramed Pharmaceuticals Inc. $3.88, representing the full amount of the profit realized in connection with these short-swing transactions. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 21:11 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 61 | $5.98 | $364.97 |
DisclosureSEC source: 0001213900-18-009128 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,087 F1 · price: On July 12, 2018, Mr. Kidron paid to Oramed Pharmaceuticals Inc. $3.88, representing the full amount of the profit realized in connection with these short-swing transactions. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:34 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 97,000 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001213900-18-001247 · f4013118nkidronnadav_oramed.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 Underlying: Common Stock · 97,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:40 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 147,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007160 · f4063017nkidron_oramed.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,000 Underlying: Common Stock · 147,000 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the company share price reaching the target of $8.0, $9.5 and $12.5 per share, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.